Crestline Management’s Immunogen Inc IMGN Stock Holding History

Crestline Management’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-108,435	Closed	-$771K	–	177
2017 Q2	$771K	Buy	+108,435	New	+$496K	0.1%	99

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crestline Management's IMGN Position: Q3 2017 in Review

Crestline Management sold out of Immunogen Inc (IMGN) in Q3 2017, closing a stake of 108,435 shares — an estimated $771K sold.

Crestline Management first reported a position in IMGN in Q2 2017 and held it in 1 quarter. The position peaked at $771K in Q2 2017. 180 funds tracked by Wall St. Rank hold IMGN as of Q3 2017.

Crestline Management reported no remaining Immunogen Inc position as of Q3 2017 after selling out during the quarter.
Crestline Management sold 108,435 Immunogen Inc shares in Q3 2017, an estimated $771K.
Crestline Management first reported a position in Immunogen Inc in Q2 2017 and held it in 1 quarter.
Crestline Management's Immunogen Inc position peaked at $771K in Q2 2017.
180 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.